國立虎尾科技大學 |

Biomarkers for Huntington's disease = improving clinical outcomes /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Biomarkers for Huntington's disease/ edited by Elizabeth A. Thomas, Georgia M. Parkin.
其他題名:	improving clinical outcomes /
其他作者:	Parkin, Georgia M.
出版者:	Cham :Springer International Publishing : : 2023.,
面頁冊數:	xvi, 475 p. :ill., digital ; : 24 cm.;
Contained By:	Springer Nature eBook
標題:	Neuropharmacology. -
電子資源:	https://doi.org/10.1007/978-3-031-32815-2
ISBN:	9783031328152

Biomarkers for Huntington's disease = improving clinical outcomes /
Biomarkers for Huntington's diseaseimproving clinical outcomes /[electronic resource] :edited by Elizabeth A. Thomas, Georgia M. Parkin. - Cham :Springer International Publishing :2023. - xvi, 475 p. :ill., digital ;24 cm. - Contemporary clinical neuroscience,2627-5341. - Contemporary clinical neuroscience..

Huntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.

ISBN: 9783031328152

Standard No.: 10.1007/978-3-031-32815-2doiSubjects--Topical Terms:

677629
Neuropharmacology.

LC Class. No.: RC394.H85 / B56 2023

Dewey Class. No.: 616.851075

Biomarkers for Huntington's disease = improving clinical outcomes /
LDR:02686nam a2200325 a 4500 001 1117319
003 DE-He213
005 20231012193305.0
006 m d
007 cr nn 008maaau
008 240126s2023 sz s 0 eng d
020 $a 9783031328152 $q (electronic bk.)
020 $a 9783031328145 $q (paper)
024 7 $a 10.1007/978-3-031-32815-2 $2 doi
035 $a 978-3-031-32815-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC394.H85 $b B56 2023
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 616.851075 $2 23
090 $a RC394.H85 $b B615 2023
245 0 0 $a Biomarkers for Huntington's disease $h [electronic resource] : $b improving clinical outcomes / $c edited by Elizabeth A. Thomas, Georgia M. Parkin.
260 $a Cham : $c 2023. $b Springer International Publishing : $b Imprint: Springer,
300 $a xvi, 475 p. : $b ill., digital ; $c 24 cm.
490 1 $a Contemporary clinical neuroscience, $x 2627-5341
520 $a Huntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.
650 2 4 $a Neuropharmacology. $3 677629
650 2 4 $a Neurophysiology. $3 582158
650 2 4 $a Neurology. $3 593894
650 1 4 $a Neuroscience. $3 569964
650 0 $a Biochemical markers. $3 582469
650 0 $a Huntington's disease $x Diagnosis. $3 1431062
700 1 $a Parkin, Georgia M. $3 1431061
700 1 $a Thomas, Elizabeth A. $3 1431060
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
830 0 $a Contemporary clinical neuroscience. $3 1064885
856 4 0 $u https://doi.org/10.1007/978-3-031-32815-2
950 $a Biomedical and Life Sciences (SpringerNature-11642)